Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn(University of San Diego), Jean‐Frédéric Colombel(Mount Sinai Hospital), Kevin Horgan(United States Military Academy), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Jiandong Lu(Guangzhou University of Chinese Medicine), Brian G. Feagan(Western University), Daniel Rachmilewitz(Hadassah Academic College), Stephen B. Hanauer(Northwestern University), Paul Rutgeerts(KU Leuven), Allan Olson, Willem J.S. de Villiers(Stellenbosch University), Gary R. Lichtenstein(University of Pennsylvania), Daniel H. Present(Communities In Schools of Orange County), Jewel Johanns(Johnson & Johnson (United States)), Walter Reinisch(Medical University of Vienna)
Cited by 475
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k